Shares of Summit Therapeutics plc (:SMMT) are showing high volatlity in today’s session as the stock has moved -2.06%, clocking in at $10.93 after a recent bid. Volatility is the dispersion of returns for a given stock.
It is quantified by short-term traders as the average difference between a stock’s daily high and daily low, then divided by the stock price. In other words, volatility refers to the amount of risk about the size of changes in a stock’s value. A higher volatility indicates that a stock’s value can be spread out over a larger range of values. The price of the stock can change wildly over a short time period in either direction. A lower volatility indicates that a stock’s value does not fluctuate dramatically, rather experiences value changes at a steady pace over a time. A security that moves $10/day with a $100 price is more volatile than one that moves $10/day with a $200 price because the percentage move is greater. Trading the most volatile stocks can be an efficient way to trade because these stocks offer the most profit potential, theoretically.
ATR and Moving Averages
Summit Therapeutics plc (:SMMT)‘s ATR is 0.96. The Average True Range (ATR) is a measure of stock volatility. The Average True Range is a exponential moving average (14-days) of the True Range. The range of a day’s trading is high-low, and True Range extends into yesterday’s closing when it falls outside of today’s range.
As we look deeper into the volatility of Summit Therapeutics plc’s stock, we see that their stock is -2.50% away from the 20-Day Simple Moving Average. Extending out to their 50-Day Simple Moving Average reveals a difference of -0.40% from current levels. Further back, their 200-Day Simple Moving Average is 31.00% away from the current price. Further, the stock is -44.66% from its 50-Day High and 59.56% from the 50-day low. The distance from the 52-Week High and Lows are important to note as well. Currently the stock is -44.66% from the high and 156.57% from the low.
Based on the current consensus analyst target Price of 28.67, analysts have a current recommendation of 1.50 on the shares. This is on a consensus basis according to Thomson Reuters. Using the formula PEG (P/E) / Annual EPS Growth (the ratio used to determine a stock’s value while taking into account the earnings’ growth), Wall Street is confident with this recommendation.
Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.